# BCAS1

## Overview
BCAS1, or Breast Carcinoma Amplified Sequence 1, is a gene that encodes the protein known as Brain Enriched Myelin Associated Protein 1. This protein is predominantly expressed in the central nervous system, where it plays a critical role in the myelination process, particularly within oligodendrocytes, the cells responsible for forming myelin sheaths around nerve fibers. BCAS1 is categorized as a cytosolic protein involved in the early stages of oligodendrocyte differentiation and is crucial for efficient nerve signal transmission (Ishimoto2017Mice; Fard2017BCAS1). The protein's expression is notably associated with active myelination phases during fetal development and early postnatal periods, and it is implicated in remyelination processes, such as those observed in multiple sclerosis lesions (Fard2017BCAS1). Additionally, BCAS1 has been linked to various neurological and oncological conditions, including schizophrenia and glioblastoma, highlighting its potential as a therapeutic target (Ishimoto2017Mice; Kuo2022A).

## Function
The BCAS1 gene encodes a protein that plays a significant role in the myelination process within the central nervous system. This protein is highly expressed in oligodendrocytes, the cells responsible for forming myelin sheaths around nerve fibers, which are crucial for efficient nerve signal transmission (Ishimoto2017Mice; Fard2017BCAS1). BCAS1 is particularly associated with a specific population of oligodendrocytes during the early stages of myelination, marking a unique stage of oligodendrocyte differentiation distinct from other markers (Fard2017BCAS1).

In the human brain, BCAS1+ oligodendrocytes are characterized by multiple radiating processes and are involved in active myelination phases, especially during fetal development and early postnatal periods (Fard2017BCAS1). These cells are transient, with their presence peaking in newborns and decreasing significantly by adulthood, although they remain relatively stable in the frontal cortex, suggesting a role in adaptive myelination (Fard2017BCAS1).

BCAS1 is also implicated in remyelination processes, as its expression is observed in multiple sclerosis lesions, indicating its potential involvement in repairing myelin damage (Fard2017BCAS1). The protein's activity is primarily cytosolic within oligodendrocytes and myelin, and it is down-regulated as differentiation progresses (Fard2017BCAS1).

## Clinical Significance
Alterations in the BCAS1 gene have been implicated in several neurological and oncological conditions. In the context of neuropsychiatric disorders, BCAS1 knockout mice exhibit schizophrenia-like behaviors, suggesting a potential link between BCAS1 disruption and schizophrenia. These mice also show hypomyelination and increased expression of inflammatory genes, indicating that BCAS1 may play a role in maintaining myelin integrity and regulating inflammation in the brain (Ishimoto2017Mice).

In multiple sclerosis (MS), BCAS1 is identified as a marker for newly generated and early myelinating oligodendrocytes. Its expression is associated with active myelination and remyelination processes, which are crucial for understanding and potentially treating MS. The presence of BCAS1+ oligodendrocytes in MS lesions suggests ongoing remyelination, even in advanced stages of the disease, highlighting its potential as a therapeutic target for promoting remyelination (Fard2017BCAS1).

In glioblastoma, a novel splice variant of BCAS1, known as BCAS1-SV1, has been identified. This variant promotes glioblastoma cell proliferation and migration by inhibiting the tumor suppressor function of β-arrestin 2. Targeting the interaction between BCAS1-SV1 and β-arrestin 2 with compounds like maackiain has shown potential in reducing tumor growth, suggesting a therapeutic avenue for glioblastoma treatment (Kuo2022A).

## Interactions
BCAS1 (Brain Enriched Myelin Associated Protein 1) is involved in several protein interactions that are significant for its function in the brain. A novel splice variant of BCAS1, known as BCAS1-SV1, has been shown to interact specifically with β-arrestin 2 (ARRB2), a protein involved in various cellular processes, including the regulation of G-protein-coupled receptor signaling. This interaction is crucial in the context of glioblastoma, as BCAS1-SV1 inhibits the tumor suppressor function of β-arrestin 2, promoting the proliferation and migration of glioblastoma cells (Kuo2022A). The interaction between BCAS1-SV1 and β-arrestin 2 involves specific regions of both proteins, with the B2 region (160-312) of BCAS1-SV1 and the A2 region (186-410) of β-arrestin 2 being necessary for this interaction (Kuo2022A).

BCAS1 also interacts with cortical F-actin through its actin-binding domain at the N-terminus and with the dynein light chain (DLC) at the C-terminus. These interactions suggest a role for BCAS1 in cytoskeletal organization and intracellular transport, which are important for myelination and neural development (Ishimoto2017Mice).


## References


[1. (Ishimoto2017Mice) Tetsuya Ishimoto, Kensuke Ninomiya, Ran Inoue, Masato Koike, Yasuo Uchiyama, and Hisashi Mori. Mice lacking bcas1, a novel myelin‐associated protein, display hypomyelination, schizophrenia‐like abnormal behaviors, and upregulation of inflammatory genes in the brain. Glia, 65(5):727–739, February 2017. URL: http://dx.doi.org/10.1002/glia.23129, doi:10.1002/glia.23129. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/glia.23129)

[2. (Kuo2022A) Yun-Hua Kuo, Huey-Shan Hung, Chia-Wen Tsai, Shao-Chih Chiu, Shih-Ping Liu, Yu-Ting Chiang, Woei-Cherng Shyu, Shinn-Zong Lin, and Ru-Huei Fu. A novel splice variant of bcas1 inhibits β-arrestin 2 to promote the proliferation and migration of glioblastoma cells, and this effect was blocked by maackiain. Cancers, 14(16):3890, August 2022. URL: http://dx.doi.org/10.3390/cancers14163890, doi:10.3390/cancers14163890. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14163890)

[3. (Fard2017BCAS1) Maryam K. Fard, Franziska van der Meer, Paula Sánchez, Ludovico Cantuti-Castelvetri, Sunit Mandad, Sarah Jäkel, Eugenio F. Fornasiero, Sebastian Schmitt, Marc Ehrlich, Laura Starost, Tanja Kuhlmann, Christina Sergiou, Verena Schultz, Claudia Wrzos, Wolfgang Brück, Henning Urlaub, Leda Dimou, Christine Stadelmann, and Mikael Simons. Bcas1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Science Translational Medicine, December 2017. URL: http://dx.doi.org/10.1126/scitranslmed.aam7816, doi:10.1126/scitranslmed.aam7816. This article has 154 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/scitranslmed.aam7816)